GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (FRA:Q9T) » Definitions » Debt-to-Asset

ME Therapeutics Holding (FRA:Q9T) Debt-to-Asset : 0.04 (As of Feb. 2025)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Debt-to-Asset?

ME Therapeutics Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2025 was €0.04 Mil. ME Therapeutics Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2025 was €0.03 Mil. ME Therapeutics Holding's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Feb. 2025 was €1.57 Mil. ME Therapeutics Holding's debt to asset for the quarter that ended in Feb. 2025 was 0.04.


ME Therapeutics Holding Debt-to-Asset Historical Data

The historical data trend for ME Therapeutics Holding's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Debt-to-Asset Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23 Aug24
Debt-to-Asset
1.90 0.06 -

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.07 0.04

Competitive Comparison of ME Therapeutics Holding's Debt-to-Asset

For the Biotechnology subindustry, ME Therapeutics Holding's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ME Therapeutics Holding's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's Debt-to-Asset falls into.


;
;

ME Therapeutics Holding Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ME Therapeutics Holding's Debt-to-Asset for the fiscal year that ended in Aug. 2024 is calculated as

ME Therapeutics Holding's Debt-to-Asset for the quarter that ended in Feb. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ME Therapeutics Holding  (FRA:Q9T) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


ME Therapeutics Holding Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


ME Therapeutics Holding Business Description

Traded in Other Exchanges
Address
177 Robson St., Vancouver, BC, CAN, V6B 0N3
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding Headlines

No Headlines